Quantum Genomics - Firibastat misses endpoints in Phase III
Quantum Genomics has announced that results from the Phase III FRESH study, investigating the use of firibastat in treatment-resistant hypertension...
590 Views
Quantum Genomics - Steady sailing as FRESH readout approaches
Quantum Genomics’ H122 results showed the company is on steady footing as it approaches a key inflection point. Top-line data from the Phase III...
677 Views
Quantum Genomics - A fresh take on cardiovascular medicine
Quantum Genomics is focused on the development of new classes of cardiovascular medicines. Firibastat, the company’s lead clinical asset, is in...
666 Views
Quantum Genomics - Termination of coverage
Edison Investment Research is terminating coverage on PIERER Mobility (PMAG), Allarity Therapeutics (ALLR), WANdisco (WAND), Quantum Genomics...
463 Views
Quantum Genomics - Phase IIb QUORUM results
Quantum Genomics has reported the results of the Phase IIb QUORUM study at the European Society of Cardiology. Unfortunately, the primary endpoint...
1k Views
No more insights